Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model
© 2022. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association..
BACKGROUND: Loss of E-cadherin expression is frequently observed in signet ring carcinoma (SRCC). People with germline mutations in CDH1, which encodes E-cadherin, develop diffuse gastric cancer at a higher rate. Loss of E-cadherin expression is thus assumed to trigger oncogenic development.
METHODS: To investigate novel therapeutic targets for gastric SRCC, we engineered an E-cadherin-deficient SRCC model in vitro using a human gastric organoid (hGO) with CDH1 knockout (KO).
RESULTS: CDH1 KO hGO cells demonstrated distinctive morphological changes similar to SRCC and high cell motility. RNA-sequencing revealed up-regulation of matrix metalloproteinase (MMP) genes in CDH1 KO hGO cells compared to wild type. MMP inhibitors suppressed cell motility of CDH1 KO hGO cells and SRCC cell lines in vitro. Immunofluorescent analysis with 95 clinical gastric cancer tissues revealed that MMP-3 was specifically abundant in E-cadherin-aberrant SRCC. In addition, CXCR4 molecules translocated onto the cell membrane after CDH1 KO. Addition of CXCL12, a ligand of CXCR4, to the culture medium prolonged cell survival of CDH1 KO hGO cells and was abolished by the inhibitor, AMD3100. In clinical SRCC samples, CXCL12-secreting fibroblasts showed marked infiltration into the cancer area.
CONCLUSIONS: E-cadherin deficient SRCCs might gain cell motility through upregulation of MMPs. CXCL12-positive cancer-associated fibroblasts could serve to maintain cancer-cell survival as a niche. MMPs and the CXCL12/CXCR4 axis represent promising candidates as novel therapeutic targets for E-cadherin-deficient SRCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 25(2022), 5 vom: 04. Sept., Seite 862-878 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamaguchi, Kyoko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CDH1 |
|---|
| Anmerkungen: |
Date Completed 12.08.2022 Date Revised 30.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10120-022-01307-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341838373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341838373 | ||
| 003 | DE-627 | ||
| 005 | 20231226012709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-022-01307-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341838373 | ||
| 035 | |a (NLM)35661943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaguchi, Kyoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2022 | ||
| 500 | |a Date Revised 30.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association. | ||
| 520 | |a BACKGROUND: Loss of E-cadherin expression is frequently observed in signet ring carcinoma (SRCC). People with germline mutations in CDH1, which encodes E-cadherin, develop diffuse gastric cancer at a higher rate. Loss of E-cadherin expression is thus assumed to trigger oncogenic development | ||
| 520 | |a METHODS: To investigate novel therapeutic targets for gastric SRCC, we engineered an E-cadherin-deficient SRCC model in vitro using a human gastric organoid (hGO) with CDH1 knockout (KO) | ||
| 520 | |a RESULTS: CDH1 KO hGO cells demonstrated distinctive morphological changes similar to SRCC and high cell motility. RNA-sequencing revealed up-regulation of matrix metalloproteinase (MMP) genes in CDH1 KO hGO cells compared to wild type. MMP inhibitors suppressed cell motility of CDH1 KO hGO cells and SRCC cell lines in vitro. Immunofluorescent analysis with 95 clinical gastric cancer tissues revealed that MMP-3 was specifically abundant in E-cadherin-aberrant SRCC. In addition, CXCR4 molecules translocated onto the cell membrane after CDH1 KO. Addition of CXCL12, a ligand of CXCR4, to the culture medium prolonged cell survival of CDH1 KO hGO cells and was abolished by the inhibitor, AMD3100. In clinical SRCC samples, CXCL12-secreting fibroblasts showed marked infiltration into the cancer area | ||
| 520 | |a CONCLUSIONS: E-cadherin deficient SRCCs might gain cell motility through upregulation of MMPs. CXCL12-positive cancer-associated fibroblasts could serve to maintain cancer-cell survival as a niche. MMPs and the CXCL12/CXCR4 axis represent promising candidates as novel therapeutic targets for E-cadherin-deficient SRCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CDH1 | |
| 650 | 4 | |a CXCR4 | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a Matrix metalloproteinase | |
| 650 | 4 | |a Signet ring carcinoma | |
| 650 | 7 | |a Cadherins |2 NLM | |
| 700 | 1 | |a Yoshihiro, Tomoyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Ariyama, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Michitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Semba, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nogami, Jumpei |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchihashi, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, Takuji |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Isobe, Taichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shindo, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Moriyama, Taiki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohuchida, Kenoki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nagao, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Tetsuo |e verfasserin |4 aut | |
| 700 | 1 | |a Hashizume, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Konomi, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Torisu, Takehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kitazono, Takanari |e verfasserin |4 aut | |
| 700 | 1 | |a Kanayama, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Oda, Yoshinao |e verfasserin |4 aut | |
| 700 | 1 | |a Kusaba, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akashi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Eishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |d 1998 |g 25(2022), 5 vom: 04. Sept., Seite 862-878 |w (DE-627)NLM115990356 |x 1436-3305 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:5 |g day:04 |g month:09 |g pages:862-878 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10120-022-01307-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 5 |b 04 |c 09 |h 862-878 | ||